GENITOURINARY CANCERS

According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

In an interview with Targeted Oncology™, Clayton Lau, MD, discussed the impact of COVID-19 on managing genitourinary cancers.

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.

Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.

Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.

Tomasz M. Beer, MD, FACP, shares unmet needs and clinical pearls for the management of patients with mCRPC.

An expert in prostate cancer comments on selecting the optimal systemic therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment.

Tomasz M. Beer, MD, FACP, shares his personal experience using darolutamide for patients with CRPC and discusses his approach to patient selection of the drug in the metastatic setting.

Dr Tomasz M. Beer reviews the use of darolutamide for nonmetastatic CRPC as seen in the ARAMIS trial and metastatic CRPC as seen in the ODENZA trial.

Prostate cancer expert Tomasz M. Beer, MD, FACP, provides insight on the use of molecular and biomarker testing for a patient with mCRPC.

Dr Tomasz M. Beer comments on approaching first-line therapy for a patient with metastatic castration-resistant prostate cancer (mCRPC).

An expert in prostate cancer discusses the typical follow-up and monitoring for a patient with metastatic CRPC.

Tomasz M. Beer, MD, FACP, presents the case of a 62-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.

Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.

Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines

Yousef Zakharia, MD, discusses the results of a phase 2 trial investigating concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder.

During a virtual Targeted Oncology Case-Based Roundtable event, Atish D. Choudhury, MD, PhD, discussed methods for treating patients with nonmetastatic prostate cancer with a group of peers.

During a virtual Targeted Oncology Case-Based Roundtable event, Tanya Dorff, MD, discussed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.